AstraZeneca (LON:AZN) Stock Price Target Raised at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN) had its target price lifted by Deutsche Bank Aktiengesellschaft from £117 to £120 in a report released on Friday morning,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on AZN. Citigroup raised their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Berenberg Bank reiterated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday, October 7th. Jefferies Financial Group reissued a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Friday, October 30th. Finally, Royal Bank Of Canada started coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating and a £145 price objective for the company. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of £155.50.

AstraZeneca Trading Up 1.3%

Shares of AZN traded up GBX 185.09 during mid-day trading on Friday, hitting £141.15. 19,870,375 shares of the company’s stock traded hands, compared to its average volume of 30,170,758. The company has a quick ratio of 0.59, a current ratio of 1.01 and a debt-to-equity ratio of 66.10. AstraZeneca has a 1 year low of £114.04 and a 1 year high of £157.32. The firm has a market capitalization of £218.91 billion, a P/E ratio of 19.99, a PEG ratio of 0.86 and a beta of 0.21. The business’s 50-day moving average price is £124.76 and its 200-day moving average price is £134.29.

Insider Buying and Selling at AstraZeneca

In related news, insider Michel Demare purchased 2,500 shares of AstraZeneca stock in a transaction dated Monday, September 14th. The stock was purchased at an average cost of £121.21 per share, for a total transaction of £303,025. 0.15% of the stock is owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.